Previous studies have shown that ALKBH5 inhibits Bcl2 degradation by reducing m6A modification, thereby regulating cell apoptosis in ovarian cancer, hepatocellular carcinoma, and cerebral ischemia-reperfusion injury [17,18,19]. This evidence concerns the gene BCL2 and hepatocellular carcinoma.